NASDAQ:ALEC Alector Q2 2026 Earnings Report $1.81 -0.05 (-2.69%) Closing price 10/2/2026 04:00 PM EasternExtended Trading$1.82 +0.01 (+0.50%) As of 10/2/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Alector EPS ResultsActual EPS-$0.21Consensus EPS -$0.23Beat/MissBeat by +$0.02One Year Ago EPSN/AAlector Revenue ResultsActual Revenue$3.32 millionExpected Revenue$1.71 millionBeat/MissBeat by +$1.61 millionYoY Revenue GrowthN/AAlector Announcement DetailsQuarterQ2 2026Date8/6/2026TimeAfter Market ClosesConference Call DateThursday, August 6, 2026Conference Call Time4:00PM ETUpcoming EarningsAlector's Q3 2026 earnings is estimated for Thursday, November 5, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 6, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Alector Earnings HeadlinesAlector, Inc. (NASDAQ:ALEC) Stock Has Average Target Price of $3.62 According to BrokeragesOctober 2 at 2:15 AM | americanbankingnews.comAlector, Inc. (ALEC) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeptember 15, 2026 | seekingalpha.comThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge. Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks. Stream his free presentation to get every buy and sell recommendation with no membership or credit card required. | Chaikin Analytics (Ad)Alector, Inc. (ALEC) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Prepared Remarks TranscriptSeptember 15, 2026 | seekingalpha.comAlector to Participate in Upcoming Healthcare ConferencesSeptember 3, 2026 | globenewswire.comAlector, Inc. (ALEC) Stock Earnings Call Transcripts - Yahoo FinanceSeptember 2, 2026 | finance.yahoo.comSee More Alector Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Alector? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Alector and other key companies, straight to your email. Email Address About AlectorAlector (NASDAQ:ALEC) is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases. The company uses its expertise in the immune system and neurobiology to investigate treatments designed to improve the brain’s ability to respond to disease and promote the removal or containment of harmful proteins and damaged cells. Alector’s pipeline has included investigational antibody therapies for conditions such as frontotemporal dementia, Alzheimer’s disease and other neurodegenerative disorders. Its lead programs have included latozinemab (AL001), an antibody being developed for frontotemporal dementia associated with progranulin deficiency, and AL002, an antibody targeting TREM2, a protein involved in microglial function. These candidates remain investigational and are not approved treatments. Founded in 2013 and headquartered in South San Francisco, California, Alector conducts research and clinical-development activities through collaborations and studies in multiple geographic regions. The company became publicly traded on the Nasdaq under the symbol ALEC in 2019. Alector was co-founded by Arnon Rosenthal, Ph.D., who has served as its chief executive officer, and its development programs have included partnerships with larger pharmaceutical companies.View Alector ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Time to Nibble on MCD Stock After it Enters Oversold Territory?McCormick Stock Trades Cheap, Offers Dividend Growth and Unilever Deal UpsideMicron’s Earnings Reveal Why the AI Memory Boom May Last LongerAnthropic's IPO Could Put Amazon's and Alphabet's Paper Profits to the TestBoeing’s Fighter Victory Opens the Door to Decades of Defense RevenueCorning and AT&T's $3 Billion Fiber Deal Reveals Where AI Spending Goes NextTarget's Holiday Blitz: Slashing Prices to Capture Market Share Upcoming Earnings PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
